Understanding hATTR Amyloidosis: Clinical Presentation, Patient Journey, and Treatment Landscape for This Rare Disease

Topic(s):

Payment Systems , Rare Diseases , Managed Care Practice Issues

Webinar Recorded on Sept. 17, 2020
Sponsored by Akcea Therapeutics

Hereditary ATTR (hATTR) amyloidosis is a rare and underrecognized multisystem disease that is characterized by rapid progression in the absence of treatment. As such, early clinical diagnosis and access to appropriate treatment are paramount to the management of this disease. The speaker will provide an overview of the ATTR amyloidosis disease subtypes, pathophysiology of disease, and the varying clinical presentations, including nonspecific symptoms that should raise suspicion of and aid in diagnosis of the disease. Additionally, this presentation will showcase the existing categories of medications used to treat hATTR amyloidosis, and associated features such as FDA-approved indications, mechanisms of action, and sites of administration.

Speaker:

Dr. Sami L. Khella, MD
Professor and Chief of Neurology
Penn Presbyterian Medical Center at University of Pennsylvania School of Medicine

This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by: